GW-6604

Cat. No.: HY-10327

CAS No.: 452342-37-9

Molecular Formula: $C_{19}H_{14}N_4$

Molecular Weight: 298.34

Target: TGF-β Receptor

Pathway: TGF-beta/Smad

Storage: 4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (335.19 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	3.3519 mL	16.7594 mL	33.5188 mL
	5 mM	0.6704 mL	3.3519 mL	6.7038 mL
	10 mM	0.3352 mL	1.6759 mL	3.3519 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

GW-6604 is an ALK5 inhibitor with an IC_{50} value of 140 nM for inhibiting its autophosphorylation, and can be used in the study of liver fibrosis[1].

In Vitro

GW-6604 (0-10 μM,) inhibits TGF-β-induced PAI-1 transcription and secretion in HepG2 cells with an IC_{50} value of 500 nM, effectively blocking the Smad-dependent response[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

GW-6604(p.o., 25-80 mg/kg, twice a day, 3 weeks) dependently inhibits hepatic COL IA1 overexpression in an acute DMN model in SD rats, reducing its expression by 80%. Normal liver weight was maintained, liver fibrosis was effectively reduced and matrix degeneration was increased[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Anne-Charlotte de Gouville, et al. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br J Pharmacol. 2005 May;145(2):166-77.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA